Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

[COPENHAGEN] Obesity drugmaker Novo Nordisk said on Wednesday (May 7) it would drop gender representation requirements for its US business following executive orders by President Donald Trump to stop ...

In other recent news, Novo Nordisk has announced its anticipation of the U.S. Food and Drug Administration enforcing a ban on compounded copies of its drugs Wegovy and Ozempic starting May 22.

Danish drugmaker Novo Nordisk has cut sales and profit forecasts due to lower-than-expected US take-up of its blockbuster GLP-1 obesity and diabetes drugs. Revenues for the maker of Ozempic and ...

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Don’t miss this ...

Shares of Novo Nordisk jumped nearly 7% on Wednesday after it said sales of its blockbuster Wegovy weight loss drug were seen improving in the second half of the year as the availability of ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks on Jim Cramer’s radar. On Friday, Mad Money host Jim Cramer discussed this week’s ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast amid weaker sales of its blockbuster Wegovy weight loss drugs.